Imaging In Evaluation Of Patients With Cushing Syndrome

10% - 20%的高皮质醇患者(Cushing？促肾上腺皮质激素（ACTH）异位产生。在大约50%的患者中，尽管进行了非常详细和广泛的影像学检查，如计算机断层扫描、磁共振成像和使用常规低剂量111-铟戊特肽（[111 - In- dtpa - d - phe]-戊特肽）的奥曲肽扫描，但仍无法找到ACTH的来源。该方案测试了[18F]-氟脱氧葡萄糖（FDG）正电子发射断层扫描（PET）扫描或使用更高剂量的[111In-DTPA-D-Phe]-戊基肽是否可以成功定位异位ACTH产生的来源。迄今为止，氟脱氧葡萄糖PET扫描在不到30%的患者中成功识别出肿瘤。低剂量octrescan在40%以上的患者中成功定位肿瘤。高剂量octrescan成功地将肿瘤定位在约10%的患者中。本研究继续发现氟脱氧葡萄糖PET扫描和高剂量octrescan与传统成像方式相比是否可以为异位库欣患者提供额外的成像策略？年代综合症。

Between 10% and 20% of patients with hypercortisolism (Cushing?s syndrome) have ectopic production of adrenocorticotropin hormone (ACTH). In approximately 50% of these patients, the source of ACTH cannot be found despite very detailed and extensive examination including imaging studies such as computed tomography scanning, magnetic resonance imaging, and octreotide scan using the conventional low dose of 111-indium pentetreotide ([111In-DTPA-D-Phe]-pentetreotide). This protocol tests whether [18F]-fluorodeoxyglucose (FDG) positron emission tomography (PET) scanning or use of a higher dose of [111In-DTPA-D-Phe]-pentetreotide can be used to localize successfully the source of ectopic ACTH production. To date fluorodeoxyglucose PET scanning successfully identified the tumor in less than 30% of patients.Low dose Octreoscan successfully localized the tumor in more than 40% of patients. High dose Octreoscan successfully localized the tumor in about 10% of patients. This study continues to find out whether fluorodeoxyglucose PET scanning and high dose Octreoscan compared to conventional imaging modalities can provide additional imaging strategies for patients with ectopic Cushing?s syndrome.